CL2019000835A1 - Proteínas de unión a antígeno de baja viscosidad y métodos de prepararlas. - Google Patents

Proteínas de unión a antígeno de baja viscosidad y métodos de prepararlas.

Info

Publication number
CL2019000835A1
CL2019000835A1 CL2019000835A CL2019000835A CL2019000835A1 CL 2019000835 A1 CL2019000835 A1 CL 2019000835A1 CL 2019000835 A CL2019000835 A CL 2019000835A CL 2019000835 A CL2019000835 A CL 2019000835A CL 2019000835 A1 CL2019000835 A1 CL 2019000835A1
Authority
CL
Chile
Prior art keywords
low viscosity
preparing
methods
antigen binding
binding proteins
Prior art date
Application number
CL2019000835A
Other languages
English (en)
Spanish (es)
Inventor
Pavel Bondarenko
Neeraj Jagdish Agrawal
Da Ren
Joon Huh
Riki Stevenson
Andrew Nichols
Richard Smith
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2019000835A1 publication Critical patent/CL2019000835A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N11/00—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties
    • G01N11/10—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material
    • G01N11/14—Investigating flow properties of materials, e.g. viscosity, plasticity; Analysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2019000835A 2016-09-29 2019-03-28 Proteínas de unión a antígeno de baja viscosidad y métodos de prepararlas. CL2019000835A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662401770P 2016-09-29 2016-09-29
US201662430773P 2016-12-06 2016-12-06
US201762546469P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
CL2019000835A1 true CL2019000835A1 (es) 2019-05-31

Family

ID=60245172

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000835A CL2019000835A1 (es) 2016-09-29 2019-03-28 Proteínas de unión a antígeno de baja viscosidad y métodos de prepararlas.
CL2021003596A CL2021003596A1 (es) 2016-09-29 2021-12-31 Método de reducción de la viscosidad de una proteína de unión a antígeno que comprende la subfamilia de la línea germinal vh3|3-33 (divisional de la solicitud no. 201900835)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021003596A CL2021003596A1 (es) 2016-09-29 2021-12-31 Método de reducción de la viscosidad de una proteína de unión a antígeno que comprende la subfamilia de la línea germinal vh3|3-33 (divisional de la solicitud no. 201900835)

Country Status (14)

Country Link
US (3) US11059908B2 (fr)
EP (1) EP3519439A2 (fr)
JP (4) JP7554047B2 (fr)
KR (2) KR102551269B1 (fr)
CN (1) CN110036031A (fr)
AU (2) AU2017336673B2 (fr)
CA (1) CA3038909A1 (fr)
CL (2) CL2019000835A1 (fr)
IL (2) IL307684B2 (fr)
MA (1) MA46359A (fr)
MX (2) MX2019003727A (fr)
SG (1) SG10201912565QA (fr)
WO (1) WO2018064307A2 (fr)
ZA (1) ZA201902297B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013004841A1 (fr) * 2011-07-06 2013-01-10 Genmab A/S Modulation de la cytotoxicité dépendante du complément par des modifications de l'extrémité c-terminale des chaînes lourdes d'anticorps
JP6367836B2 (ja) 2013-02-07 2018-08-01 ザ ジェネラル ホスピタル コーポレイション Ｔ制御性細胞の増殖または枯渇方法
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
DK3447075T3 (da) 2015-05-15 2023-11-13 Massachusetts Gen Hospital Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
WO2017040312A1 (fr) 2015-08-28 2017-03-09 The General Hospital Corporation Anticorps agonistes anti-récepteurs de type ii du facteur de nécrose tumorale
KR20250007678A (ko) 2016-05-13 2025-01-14 더 제너럴 하스피탈 코포레이션 길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
KR102725918B1 (ko) 2018-05-18 2024-11-04 서울반도체 주식회사 발광 다이오드, 발광 다이오드 모듈 및 그것을 갖는 표시 장치
WO2020041361A1 (fr) * 2018-08-20 2020-02-27 The General Hospital Corporation Polypeptides antagonistes de la superfamille des récepteurs au facteur de nécrose tumorale
EP3880711A4 (fr) 2018-11-15 2022-12-28 The General Hospital Corporation Polypeptides agonistes de la superfamille des récepteurs au facteur de nécrose tumorale
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
CA3133074A1 (fr) * 2019-03-11 2020-09-17 Memorial Sloan Kettering Cancer Center Anticorps cd22 et leurs procedes d'utilisation
GB2590642B (en) * 2019-12-20 2024-02-14 Kymab Ltd Improved lambda antibodies
US20230312729A1 (en) * 2019-06-26 2023-10-05 Amunix Pharmaceuticals, Inc. Egfr antigen binding fragments and compositions comprising same
MX2022005595A (es) * 2019-11-07 2022-08-10 Amgen Inc Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).
CA3163358A1 (fr) 2019-12-03 2021-06-10 Evotec International Gmbh Proteines de liaison a l'antigene associees a l'interferon et leurs utilisations
WO2021202013A1 (fr) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anticorps anti-gipr et ses procédés d'utilisation
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
WO2022011264A2 (fr) * 2020-07-10 2022-01-13 The Wistar Institute Of Anatomy And Biology Constructions d'anticorps d'adn à utiliser contre un rotavirus
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024209050A1 (fr) 2023-04-05 2024-10-10 Antag Therapeutics Aps Modulateurs de l'activité du gip et intolérance orthostatique
TWI871793B (zh) * 2023-10-06 2025-02-01 宏碁股份有限公司 端對端的並排影像處理系統及方法
WO2026003765A1 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations d'anticorps anti-récepteur 1 de l'interleukine 1
WO2026006472A2 (fr) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions d'anticorps il-1r1 et leurs procédés de production et d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
WO2011017330A1 (fr) 2009-08-04 2011-02-10 Genentech Inc Formulations de polypeptide concentrées à viscosité réduite
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2012229251A1 (en) 2011-03-11 2013-09-12 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CA2904805A1 (fr) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Anticorps asymetriques modifies liant a la recepteur fc et procedes d'utilisation
EP3026061A1 (fr) * 2014-11-26 2016-06-01 Novo Nordisk A/S Mutagenèse dirigée sur site d'anticorps trem-1 pour diminuer la viscosite
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法

Also Published As

Publication number Publication date
WO2018064307A3 (fr) 2018-07-05
AU2025200735A1 (en) 2025-02-27
KR102551269B1 (ko) 2023-07-05
WO2018064307A4 (fr) 2018-09-27
JP7554047B2 (ja) 2024-09-19
IL307684B2 (en) 2025-04-01
CL2021003596A1 (es) 2022-08-19
CA3038909A1 (fr) 2018-04-05
AU2017336673A1 (en) 2019-04-18
EP3519439A2 (fr) 2019-08-07
JP2026110678A (ja) 2026-07-02
MA46359A (fr) 2019-08-07
US11993663B2 (en) 2024-05-28
US12637521B2 (en) 2026-05-26
MX2024008936A (es) 2024-07-29
JP2023178409A (ja) 2023-12-14
AU2017336673B2 (en) 2024-11-07
KR102806206B1 (ko) 2025-05-13
IL265692B1 (en) 2023-11-01
SG10201912565QA (en) 2020-02-27
IL265692B2 (en) 2024-03-01
KR20230107696A (ko) 2023-07-17
KR20190053271A (ko) 2019-05-17
MX2019003727A (es) 2019-08-05
US20240343832A1 (en) 2024-10-17
IL307684B1 (en) 2024-12-01
JP7882670B2 (ja) 2026-06-30
US20190233543A1 (en) 2019-08-01
JP2019532063A (ja) 2019-11-07
JP2022081654A (ja) 2022-05-31
CN110036031A (zh) 2019-07-19
US20210371544A1 (en) 2021-12-02
WO2018064307A2 (fr) 2018-04-05
IL265692A (en) 2019-05-30
IL307684A (en) 2023-12-01
US11059908B2 (en) 2021-07-13
ZA201902297B (en) 2019-12-18

Similar Documents

Publication Publication Date Title
MX2019003727A (es) Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
MX2021003435A (es) Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CL2019000082A1 (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso.
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112016026773A2 (pt) domínios variáveis de imunoglobulina aperfeiçoados
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
BR112017003582A2 (pt) anticorpos, composições e usos
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR122020006907B8 (pt) Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
CR20180065A (es) Constructos de anticuerpo biespecíficos que se unen a egfrviii y cd3
MX384419B (es) Constructos de anticuerpos para cdh19 y cd3
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112018015754A2 (pt) anticorpos anti-tnf, composições, métodos e uso para o tratamento ou prevenção de diabetes tipo 1
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
MX2017006866A (es) Pares de unión para producción de péptidos.